A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine
The coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. Herein,...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/9/987 |
| _version_ | 1797516983031300096 |
|---|---|
| author | Immacolata Polvere Serena Voccola Alfredina Parrella Gaetano Cardinale Lucrezia Zerillo Romualdo Varricchio Jessica Raffaella Madera Romania Stilo Pasquale Vito Tiziana Zotti |
| author_facet | Immacolata Polvere Serena Voccola Alfredina Parrella Gaetano Cardinale Lucrezia Zerillo Romualdo Varricchio Jessica Raffaella Madera Romania Stilo Pasquale Vito Tiziana Zotti |
| author_sort | Immacolata Polvere |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. Herein, we analyzed differences in the antibody response elicited by inoculation of the Pfizer/BioNTech vaccine through a peptide-based enzyme-linked immunosorbent assay (ELISA) that utilizes synthetic peptides derived from the spike protein in the immuno-adsorbent phase. Immunoreactivity against synthetic peptides was measured at different time points from vaccination and was also correlated with the SARS-CoV-2 neutralizing capacity. Our results indicate that all vaccinated subjects except one show reactive antibodies to at least one peptide at both 30 and 60 days after injection of the first dose. Only one of the 19 analyzed subjects showed no antibody response toward any of the selected peptides, consistently with a lower neutralizing capacity. More importantly, our data showed that the antibody response elicited by inoculation of the two doses of the Pfizer vaccine appears to be qualitatively individual, both in the type of recognized peptides and in the temporal persistence of the antibody response. Together with previous published data, our findings suggest that for effective pandemic control, it is important to constantly monitor the antibody protection in the population, and the assay described here could be a valid tool for this purpose. |
| first_indexed | 2024-03-10T07:08:29Z |
| format | Article |
| id | doaj.art-4210d1eb58f846f184e4f78150feac58 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T07:08:29Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-4210d1eb58f846f184e4f78150feac582023-11-22T15:34:29ZengMDPI AGVaccines2076-393X2021-09-019998710.3390/vaccines9090987A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA VaccineImmacolata Polvere0Serena Voccola1Alfredina Parrella2Gaetano Cardinale3Lucrezia Zerillo4Romualdo Varricchio5Jessica Raffaella Madera6Romania Stilo7Pasquale Vito8Tiziana Zotti9Dipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyGenus Biotech, Università Degli Studi del Sannio, SS Appia, 82030 Apollosa, ItalyConsorzio Sannio Tech, SS Appia, 82030 Apollosa, ItalyConsorzio Sannio Tech, SS Appia, 82030 Apollosa, ItalyDipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyGenus Biotech, Università Degli Studi del Sannio, SS Appia, 82030 Apollosa, ItalyDipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyDipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyDipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyDipartimento di Scienze e Tecnologie, Università Degli Studi del Sannio, Via dei Mulini, 82100 Benevento, ItalyThe coronavirus disease 2019 (COVID-19) mRNA vaccine developed by Pfizer/BioNTech has been shown to be capable of developing an excellent antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, with good production of neutralizing antibodies. Herein, we analyzed differences in the antibody response elicited by inoculation of the Pfizer/BioNTech vaccine through a peptide-based enzyme-linked immunosorbent assay (ELISA) that utilizes synthetic peptides derived from the spike protein in the immuno-adsorbent phase. Immunoreactivity against synthetic peptides was measured at different time points from vaccination and was also correlated with the SARS-CoV-2 neutralizing capacity. Our results indicate that all vaccinated subjects except one show reactive antibodies to at least one peptide at both 30 and 60 days after injection of the first dose. Only one of the 19 analyzed subjects showed no antibody response toward any of the selected peptides, consistently with a lower neutralizing capacity. More importantly, our data showed that the antibody response elicited by inoculation of the two doses of the Pfizer vaccine appears to be qualitatively individual, both in the type of recognized peptides and in the temporal persistence of the antibody response. Together with previous published data, our findings suggest that for effective pandemic control, it is important to constantly monitor the antibody protection in the population, and the assay described here could be a valid tool for this purpose.https://www.mdpi.com/2076-393X/9/9/987COVID-19vaccineantibodiesELISApeptides |
| spellingShingle | Immacolata Polvere Serena Voccola Alfredina Parrella Gaetano Cardinale Lucrezia Zerillo Romualdo Varricchio Jessica Raffaella Madera Romania Stilo Pasquale Vito Tiziana Zotti A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine Vaccines COVID-19 vaccine antibodies ELISA peptides |
| title | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine |
| title_full | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine |
| title_fullStr | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine |
| title_full_unstemmed | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine |
| title_short | A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine |
| title_sort | peptide based assay discriminates individual antibody response to the covid 19 pfizer biontech mrna vaccine |
| topic | COVID-19 vaccine antibodies ELISA peptides |
| url | https://www.mdpi.com/2076-393X/9/9/987 |
| work_keys_str_mv | AT immacolatapolvere apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT serenavoccola apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT alfredinaparrella apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT gaetanocardinale apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT lucreziazerillo apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT romualdovarricchio apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT jessicaraffaellamadera apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT romaniastilo apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT pasqualevito apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT tizianazotti apeptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT immacolatapolvere peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT serenavoccola peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT alfredinaparrella peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT gaetanocardinale peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT lucreziazerillo peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT romualdovarricchio peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT jessicaraffaellamadera peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT romaniastilo peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT pasqualevito peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine AT tizianazotti peptidebasedassaydiscriminatesindividualantibodyresponsetothecovid19pfizerbiontechmrnavaccine |